Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S294981982600141X?dgcid=rss_sd_all
Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S294981982600141X?dgcid=rss_sd_all
“Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆.” ESMO Gastrointestinal Oncology.
@article{article93715,
title = {Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S294981982600141X?dgcid=rss_sd_all}
}